Dew, I spent a bunch of time on this and almost deleted it. Same track on damages.
I could, and would, make an argument that all damages or potential damages accrue at the time the suit is filed and not on what events might or might not happen after the suit is filed. Otherwise, a suit might never be decided.
Most law suits, I was involved with, had a specific date the damages happened. The damages can continue to accrue.
To pile on a total different event, New AG, that happens after the suit is filed, to change the damages awarded, might not fly. Just saying.
I am well aware this is a patent infringement suit.
Next if MNTA does not prevail they need to take a serious look at buying another company or drugs while they work on a new pipeline.
Robert Langer is still a consultant. How about a trip to MIT and buy another potential drug or drugs with cash?
I suggested buying one company with a new drug mfg. plant coming on line in DEC. 30M sales, where the stock has been hit hard, as a buyout potential. MNTA needs to be covering potential steal deal to buy out there.
As for the post about NFLX. The top 11 shareholders that lost 41.47 a share today could have caused the mother of all short squeezes on MNTA with the money they lost today. That is not counting individual investor losses. OUCH.
One post said they don't see Copaxone until 2013 or 2014 as they can't replicate a MS generic. Not what I have heard listening to the conference calls. They have sounded pretty confident on the replication. The question is if they have it covered in all aspects on the patents. They did not do that additional study for no reason.
Depending how this PI comes out, MNTA can pull the same thing on other companies if it decided it can be a free for all with no holds barred or patents honored.
Enough doom and gloom, and now management needs to figure out how to blow the socks off this stock.
All just my opinion.
